The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials

被引：13

作者：

Fazzari, Francesco G. T. ^{[1
]}

Rose, Foster ^{[1
]}

Pauls, Mehrnoosh ^{[2
]}

Guay, Evelyne ^{[1
]}

Ibrahim, Mohammed F. K. ^{[3
]}

Basulaiman, Bassam ^{[4
]}

Tu, Megan ^{[5
]}

Hutton, Brian ^{[6
,7
]}

Nicholas, Garth ^{[5
,8
]}

Ng, Terry L. ^{[5
,8
]}

机构：

[1] Univ Ottawa, Fac Med, 451 Smyth Rd 2044, Ottawa, ON K1H 8M5, Canada

[2] Univ British Columbia, BC Canc Ctr, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada

[3] Northern Ontario Sch Med, Med Oncol, Div Clin Sci, 955 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada

[4] King Fahad Med City, Comprehens Canc Ctr, Med Oncol Dept, Makkah Al Mukarramah Branch Rd, Riyadh 11564, Saudi Arabia

[5] Ottawa Hosp Res Inst, 1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada

[6] Ottawa Hosp Res Inst, Clin Epidemiol Program, 1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada

[7] Univ Ottawa, 1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada

[8] Univ Ottawa, Dept Med, Div Med Oncol, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2022年 / 169卷

关键词：

Chemotherapy; Antibody-drug conjugate; Anti-angiogenic; Immunotherapy; Recurrent glioblastoma; Systemic therapy; Systematic review; PHASE-II TRIAL; DOSE-INTENSE TEMOZOLOMIDE; BEVACIZUMAB PLUS LOMUSTINE; DOUBLE-BLIND; ADJUVANT TEMOZOLOMIDE; COMBINATION; INHIBITOR; BIOMARKER; EFFICACY; ADULTS;

D O I：

10.1016/j.critrevonc.2021.103540

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Conduct a systematic review of the effectiveness of systemic therapies for adult recurrent glioblastoma (rGBM). Methods: We electronically searched for randomized controlled trials from three major databases and four conferences from 2009-Dec 2020. Two independent reviewers conducted screening, data extraction, and quality assessment. Results: 48 randomized trials were identified. Outcome reporting was inconsistent: overall survival (OS) in 46 studies, progression free survival in 37 studies, 6-month PFS in 30 studies, objective response rate in 28 studies, and 6-month OS in 7 studies. Network meta-analysis was not feasible due to heterogeneity in outcome reporting and single-study linkages. Most studies compared lomustine (8 studies), bevacizumab (18), or temozolomide (8) with other treatments. The median OS across all studies ranged from 3 to 17.6 months. Conclusions: Based on level one evidence, there is no superior systemic regimen for rGBM. rGBM is a heterogeneous population with no single regimen demonstrating OS benefit.

引用

页数：20

共 98 条

[1]

AbbVie, 2021, ABBVIE PROV UPD DEP

[2] Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE [J].

Alexander, Brian M. ;

Ba, Sujuan ;

Berger, Mitchel S. ;

Berry, Donald A. ;

Cavenee, Webster K. ;

Chang, Susan M. ;

Cloughesy, Timothy F. ;

Jiang, Tao ;

Khasraw, Mustafa ;

Li, Wenbin ;

Mittman, Robert ;

Poste, George H. ;

Wen, Patrick Y. ;

Yung, W. K. Alfred ;

Barker, Anna D. .

CLINICAL CANCER RESEARCH, 2018, 24 (04) :737-743

[3] Biomarker-based adaptive trials for patients With glioblastoma-lessons from I-SPY 2 [J].

Alexander, Brian M. ;

Wen, Patrick Y. ;

Trippa, Lorenzo ;

Reardon, David A. ;

Yung, Wai-Kwan Alfred ;

Parmigiani, Giovanni ;

Berry, Donald A. .

NEURO-ONCOLOGY, 2013, 15 (08) :972-978

[4] REOPERATION IN THE TREATMENT OF RECURRENT INTRACRANIAL MALIGNANT GLIOMAS [J].

AMMIRATI, M ;

GALICICH, JH ;

ARBIT, E ;

LIAO, Y .

NEUROSURGERY, 1987, 21 (05) :607-614

[5]

Arrillaga-Romany I, 2019, NEURO-ONCOLOGY, V21, P27

[6] Survival and functional status after resection of recurrent glioblastoma multiforme [J].

Barker, FG ;

Chang, SM ;

Gutin, PH ;

Malec, MK ;

McDermott, MW ;

Prados, MD ;

Wilson, CB .

NEUROSURGERY, 1998, 42 (04) :709-720

[7] Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma [J].

Batchelor, Tracy T. ;

Mulholland, Paul ;

Neyns, Bart ;

Nabors, L. Burt ;

Campone, Mario ;

Wick, Antje ;

Mason, Warren ;

Mikkelsen, Tom ;

Phuphanich, Surasak ;

Ashby, Lynn S. ;

DeGroot, John ;

Gattamaneni, Rao ;

Cher, Lawrence ;

Rosenthal, Mark ;

Payer, Franz ;

Juergensmeier, Juliane M. ;

Jain, Rakesh K. ;

Sorensen, A. Gregory ;

Xu, John ;

Liu, Qi ;

van den Bent, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) :3212-3218

[8] Bayesian clinical trials [J].

Berry, DA .

NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (01) :27-36

[9] Analysis of health-related quality of life in patients with brain tumors prior and subsequent to radiotherapy [J].

Bitterlich, Claudia ;

Vordermark, Dirk .

ONCOLOGY LETTERS, 2017, 14 (02) :1841-1846

[10] Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study [J].

Bogdahn, U. ;

Hau, P. ;

Stockhammer, G. ;

Venkataramana, N. K. ;

Mahapatra, A. K. ;

Suri, A. ;

Balasubramaniam, A. ;

Nair, S. ;

Oliushine, V. ;

Parfenov, V. ;

Poverennova, I. ;

Zaaroor, M. ;

Jachimczak, P. ;

Ludwig, S. ;

Schmaus, S. ;

Heinrichs, H. ;

Schlingensiepen, K-H .

NEURO-ONCOLOGY, 2011, 13 (01) :132-142

← 1 2 3 4 5 6 7 8 9 10 →